Axsome Therapeutics stockholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting

Axsome Therapeutics, Inc.

Re-elected Herriot Tabuteau (33.3M for, 0.5M withheld) and Mark Coleman (27.1M for, 6.7M withheld) as Class III directors.
Ratified Deloitte & Touche as independent auditor for FY2024 with 39.1M for, 0.15M against.
Advisory vote approved named executive officer compensation: 32.9M for, 0.87M against.
Approximately 84% of eligible shares (39.9M of 47.5M) were represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.